Abstract
Several years ago, the FDA alerted physicians to case reports of acute pancreatitis in patients treated with the incretin-based diabetes drugs exenatide (Byetta; a glucagon-like peptide-1 [GLP-1] receptor agonist) and sitagliptin (Januvia; a dipeptidyl peptidase 4 [DPP-4] inhibitor). In two recent studies, investigators determined whether incretin-based treatment raises risk for acute pancreatitis in patients with type …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
